Skip to main content

FDA Adopts Pharsight Simulation Program for HIV Drug Development

NEW YORK, Feb. 25 (GenomeWeb News) - The US Food and Drug Administration has used a quantitative-based modeling and simulation program designed by Pharsight to help it design an end-of-Phase IIa trial for an anti-HIV drug, Pharsight said today.

 

The relationship between Pharsight and the FDA is partly the result of the agency's EOPIIa program, which is part of the Critical Path Initiative. The program enables the FDA to provide sponsors of clinical trials with input earlier in the drug-development cycle.

 

Pharsight said it believes that quantitative-based modeling and simulation during drug development can increase the productivity and efficiency of the process.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.